Literature DB >> 25616578

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.

Mercedes Borge1, María Belén Almejún2, Enrique Podaza2, Ana Colado2, Horacio Fernández Grecco3, María Cabrejo3, Raimundo F Bezares4, Mirta Giordano5, Romina Gamberale5.   

Abstract

Entities:  

Keywords:  ibrutinib; phagocytosis; rituximab-dependent

Mesh：

Substances：

Year:  2015        PMID： 25616578      PMCID： PMC4380736          DOI： 10.3324/haematol.2014.119669

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Christian R Geest; Eric Eldering; Betty Y Chang; Joseph J Buggy; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

2.  Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.

Authors:  Sarwish Rafiq; Jonathan P Butchar; Carolyn Cheney; Xiaokui Mo; Rossana Trotta; Michael Caligiuri; David Jarjoura; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  J Immunol       Date:  2013-02-15       Impact factor: 5.422

3.  Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Authors:  Fabio Da Roit; Patrick J Engelberts; Ronald P Taylor; Esther C W Breij; Giuseppe Gritti; Alessandro Rambaldi; Martino Introna; Paul W H I Parren; Frank J Beurskens; Josée Golay
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

4.  Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; June H Myklebust; Bindu Varghese; Saar Gill; Max Jan; Adriel C Cha; Charles K Chan; Brent T Tan; Christopher Y Park; Feifei Zhao; Holbrook E Kohrt; Raquel Malumbres; Javier Briones; Randy D Gascoyne; Izidore S Lossos; Ronald Levy; Irving L Weissman; Ravindra Majeti
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

5.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

6.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

7.  A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.

Authors:  Minna Taskinen; Marja-Liisa Karjalainen-Lindsberg; Heidi Nyman; Leena-Maija Eerola; Sirpa Leppä
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

8.  High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.

Authors:  Danielle Canioni; Gilles Salles; Nicolas Mounier; Nicole Brousse; Marie Keuppens; Frank Morchhauser; Thierry Lamy; Anne Sonet; Marie-Christine Rousselet; Charles Foussard; Luc Xerri
Journal:  J Clin Oncol       Date:  2007-12-17       Impact factor: 44.544

9.  Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn.

Authors:  C J Fitzer-Attas; M Lowry; M T Crowley; A J Finn; F Meng; A L DeFranco; C A Lowell
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

10.  The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Authors:  Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307
View more
  21 in total

1.  Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Authors:  Li Ren; Amanda Campbell; Huiqing Fang; Shalini Gautam; Saranya Elavazhagan; Kavin Fatehchand; Payal Mehta; Andrew Stiff; Brenda F Reader; Xiaokui Mo; John C Byrd; William E Carson; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

2.  The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.

Authors:  Josée Golay; Greta Ubiali; Martino Introna
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

3.  The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.

Authors:  Sarah E M Herman; Arnau Montraveta; Carsten U Niemann; Helena Mora-Jensen; Michael Gulrajani; Fanny Krantz; Rose Mantel; Lisa L Smith; Fabienne McClanahan; Bonnie K Harrington; Dolors Colomer; Todd Covey; John C Byrd; Raquel Izumi; Allard Kaptein; Roger Ulrich; Amy J Johnson; Brian J Lannutti; Adrian Wiestner; Jennifer A Woyach
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

4.  Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.

Authors:  Samantha M Jaglowski; Jeffrey A Jones; Veena Nagar; Joseph M Flynn; Leslie A Andritsos; Kami J Maddocks; Jennifer A Woyach; Kristie A Blum; Michael R Grever; Kelly Smucker; Amy S Ruppert; Nyla A Heerema; Gerard Lozanski; Mona Stefanos; Brian Munneke; Jamie-Sue West; Jutta K Neuenburg; Danelle F James; Nathan Hall; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-06-26       Impact factor: 22.113

Review 5.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

6.  Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

Authors:  Carsten U Niemann; Helena I Mora-Jensen; Eman L Dadashian; Fanny Krantz; Todd Covey; Shih-Shih Chen; Nicholas Chiorazzi; Raquel Izumi; Roger Ulrich; Brian J Lannutti; Adrian Wiestner; Sarah E M Herman
Journal:  Clin Cancer Res       Date:  2017-06-23       Impact factor: 12.531

Review 7.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

8.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

9.  Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.

Authors:  A K Church; K R VanDerMeid; N A Baig; A M Baran; T E Witzig; G S Nowakowski; C S Zent
Journal:  Clin Exp Immunol       Date:  2015-10-28       Impact factor: 4.330

10.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.